(LPTX) – Hot FDA News
-
Leap Therapeutics (LPTX) Reports Collaboration With EORTC to Evaluate DKN-01 in Combination with PD-L1 Cancer Immunotherapy and Chemotherapy In Esophagogastric and Biliary Tract Cancers
-
Leap Therapeutics (LPTX) Reports Positive DKN-01 Clinical Data in Biliary Tract Cancers at American Society of Clinical Oncology 2017 Annual Meeting
Back to LPTX Stock Lookup
